Rotenone, Paraquat and Parkinson’s Disease

Caroline M. Tanner, Freya Kamel, G. Webster Ross, Jane A. Hoppin, Samuel M. Goldman, Monica Korell, Connie Marras, Grace S. Bhudhikanok, Meike Kasten, Anabel R. Chade, Kathleen Comyns, Marie Barber Richards, Cheryl Meng, Benjamin Priestley, Hubert H. Fernandez, Franca Cambi, David M. Umbach, Aaron Blair, Dale P. Sandler, and J. William Langston

doi: 10.1289/ehp.1002839 (available at http://dx.doi.org/)
Online 26 January 2011
Rotenone, Paraquat and Parkinson’s Disease

Caroline M Tanner\textsuperscript{1}; Freya Kamel\textsuperscript{2}; G Webster Ross\textsuperscript{3}; Jane A Hoppin\textsuperscript{2}; Samuel M Goldman\textsuperscript{1}; Monica Korell\textsuperscript{1}; Connie Marras\textsuperscript{4}; Grace S Bhudhikanok\textsuperscript{1}; Meike Kasten\textsuperscript{5}; Anabel R Chade\textsuperscript{6}; Kathleen Comyns\textsuperscript{1}; Marie Barber Richards\textsuperscript{2, 7}; Cheryl Meng\textsuperscript{1}; Benjamin Priestley\textsuperscript{1}; Hubert H Fernandez\textsuperscript{9}; Franca Cambi\textsuperscript{9}; David M Umbach\textsuperscript{10}; Aaron Blair\textsuperscript{11}; Dale P Sandler\textsuperscript{2}; J William Langston\textsuperscript{1}

1. The Parkinson’s Institute, Sunnyvale, CA
2. Epidemiology Branch, National Institute of Environmental Health Sciences, NIH, DHHS, Research Triangle Park, NC
3. Veterans Affairs Pacific Islands Health Care System, Honolulu, Hawaii
4. Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada
5. Departments of Neurology and Clinical and Molecular Neurogenetics, University of Lubeck, Lubeck, Germany
6. Institute of Cognitive Neurology (INECO), Institute of Neuroscience, Favaloro University, Buenos Aires, Argentina
7. Westat Inc., Durham, NC
8. Center for Neurological Restoration, Cleveland Clinic, Cleveland, OH
9. Department of Neurology, University of Kentucky, Lexington, KY
10. Biostatistics Branch, National Institute of Environmental Health Sciences, NIH, DHHS, Research Triangle Park, NC
11. Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, NCI, NIH, DHHS, Bethesda, MD

Corresponding Author: Caroline Tanner, MD, PhD, Parkinson’s Institute, 675 Almanor Ave, Sunnyvale, CA 94085, Email: ctannermd@aol.com, Phone: 408-734-2800, FAX: 408-734-8455
Running Title: Rotenone, Paraquat and Parkinson’s Disease

Key words: Aging, Agricultural Epidemiology, Environmental Epidemiology, Epidemiology, Fungicides, Herbicides, Insecticides, Persistent Organic Pollutants, Pesticides

Acknowledgements:
Supported in part by the Intramural Research Program of the NIH (NIEHS grants Z01-ES044007 and Z01-ES049030, NCI grant Z01-CP010119), NIEHS grant R01-ES10803, and James and Sharron Clark. The authors thank the participants, the research team, Timothy Greenamyre, MD, PhD for manuscript review and Jennifer Wright for editorial assistance.

Competing Financial Interests Declaration:
CT, WL, CM, HF, WR, and SG, in addition to their listed affiliations, serve as consultants and receive financial support from many sources, including pharmaceutical companies who manufacture or do research on medications for Parkinson's disease and former and current welding products manufacturers, and serve on advisory boards for various foundations. The Parkinson's Institute treats patients with PD. Westat is an employee-owned company.

Abbreviations:
AHS: Agricultural Health Study
ATSDR: Agency for Toxic Substances and Disease Registry
CDC: Centers for Disease Control
CI: Confidence interval
EPA: Environmental Protection Agency
EXTOXNET: Extension Toxicology Network
FAME: Farming and Movement Evaluation study
MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
OR: Odds ratio
PD: Parkinson’s disease
Abstract

**Background**: Mitochondrial dysfunction and oxidative stress are pathophysiologic mechanisms implicated in experimental models and genetic forms of Parkinson’s disease (PD). Certain pesticides may affect these mechanisms, but no pesticide has been definitively associated with PD in humans.

**Objectives**: To determine whether pesticides that cause mitochondrial dysfunction or oxidative stress are associated with PD or clinical features of parkinsonism in humans

**Methods**: We assessed lifetime use of pesticides selected by mechanism in a case-control study nested in the Agricultural Health Study (AHS). PD was diagnosed by movement disorders specialists. Controls were a stratified random sample of all AHS participants frequency-matched to cases by age, gender, and state at approximately 3 controls: 1 case.

**Results**: In 110 PD cases and 358 controls, PD was associated with use of a group of pesticides that inhibit mitochondrial Complex I (OR 1.7, 95% CI 1.0, 2.8) including rotenone (OR 2.5, 95% CI 1.3, 4.7), and with use of a group of pesticides that cause oxidative stress (OR 2.0, 95% CI 1.2, 3.6) including paraquat (OR 2.5, 95% CI 1.4, 4.7).

**Conclusions**: PD was positively associated with two groups of pesticides defined by mechanisms implicated experimentally: those which impair mitochondrial function and those which increase oxidative stress, supporting a role for these mechanisms in PD pathophysiology.
Introduction

Mitochondrial dysfunction and oxidative stress have long been implicated as pathophysiologic mechanisms underlying PD (Betarbet et al. 2000; Di Monte et al. 2002). Genetic forms of PD associated with mutations in the alpha-synuclein, PARKIN, PINK1 or DJ-1 genes may involve these mechanisms (Henchcliffe and Beal 2008). In experimental models, the pesticides paraquat, which causes oxidative stress, and rotenone, which inhibits mitochondrial complex I, both induce loss of nigral dopaminergic neurons and behavioral changes associated with human PD (Henchcliffe and Beal 2008). Yet despite decades of laboratory study, neither pesticide has been definitively associated with PD in humans. Previous studies have reported associations with paraquat, but results are inconsistent and, in general, studies included few exposed cases; evidence concerning rotenone is sparse (Table 1). To assess the relevance of experimental results to human PD, we investigated the association of PD with use of pesticides linked to Complex I inhibition or oxidative stress in a population with well-characterized pesticide exposure.

The Farming and Movement Evaluation study (FAME) is a case-control study nested in the Agricultural Health Study (AHS), a prospective study including 84,740 private pesticide applicators (mostly farmers) and their spouses, recruited in 1993-97 in Iowa and North Carolina (Alavanja et al. 1996). Pesticide use is reported reliably by these applicators (Blair et al. 2002; Hoppin et al. 2002). We previously reported that self-reported PD was associated with increasing lifetime days of use of any pesticide but no specific pesticide could be definitely implicated (Kamel et al. 2007). In the current study, we assessed lifelong use of pesticides with toxicant mechanisms relevant to PD. Because 15-25% of self-reported PD diagnoses in community populations may be
incorrect (Tolosa et al. 2006), we based diagnoses on in-person examination and consensus of two experts, minimizing diagnostic misclassification and enabling analyses of clinical features. We report here results from our investigation of pesticides previously associated with mitochondrial Complex I inhibition (termed “Complex I inhibitors”) or oxidative stress (termed “oxidative stressors”).

Methods

Case and control identification: From among AHS cohort members who were private pesticide applicators (mostly farmers) and their spouses, we identified persons suspected to have PD based on diagnoses from self-reports or state mortality files. We selected potential controls by stratified random sampling of all AHS participants. Cohort members who were ultimately diagnosed with PD or parkinsonism, dead, cognitively impaired or seriously ill were not eligible to be controls. Controls were frequency-matched to cases by age (<40, 40-49, 50-59, 60-64, 65-69, ≥70 years), gender, and state (Iowa or North Carolina) at a ratio of approximately three controls per case.

Living suspect cases and all potential controls were assessed during home visits. Movement disorder specialist neurologists (subsequently called “neurologists”) assessed all cases and 5% of controls. Neurologist-trained technicians assessed the remaining controls. The in-person assessment included factors used to diagnose PD and to distinguish PD from other disorders, including a standardized medical and neurological history, the Cognitive Abilities Screening Instrument (Teng et al. 1994), a scripted, standardized videotaped assessment of parkinsonism, a handwriting sample, medications and the University of Pennsylvania brief smell identification test (Sensonics, Inc., Haddon Heights, NJ) (Doty et al. 1996). Neurologists’ assessments also included a standardized neurological examination, orthostatic hypotension
assessment, the Unified Parkinson’s Disease Rating Scale (Fahn and Elton 1987) and
the Tremor Rating Scale (Fahn et al. 1993). Technician-assessed controls with signs
suggesting parkinsonism were subsequently assessed by a neurologist.

Diagnosis was determined by agreement of two neurologists (CMT and either GWR,
CM, AC, or MK), following independent review of all available diagnostic information
(medical records, in-person examination records and videotaped examination) for all
suspect cases and when PD was suspected in a control. Established criteria for PD
and related disorders were used (Bain et al. 2000; Elble 2000; Gelb et al. 1999; Gilman
et al. 1999; Hughes et al. 1992; Langston et al. 1992; Litvan et al. 1996; McKeith et al.
1996).

FAME was approved by institutional review boards for the Parkinson’s Institute, NIH,
Social and Scientific Systems, Inc. (Durham, NC), the University of Iowa (Iowa field
station), and Battelle, Inc. (North Carolina field station). All participants provided written
informed consent.

Exposure Assessment: We used computer-assisted telephone interviews to obtain
detailed information on pesticide use from age 14 onward for 31 selected pesticides
(Supplemental Table 1), as well as covariate information including lifelong smoking and
family history of PD. For subjects who were unable to complete interviews, we used
proxy informants. Although all controls were living and competent when enrolled, some
later became unable to participate and a proxy informant was used. We considered only
pesticide use occurring before a reference date (cases: age at PD diagnosis; controls:
median age of PD diagnosis for cases within the corresponding age-, gender-, and
state-specific stratum). For each pesticide, we determined ever use (used one or more times) and lifetime days of use (determined for each farm job by multiplying years of use by average days of use per year, and then summing across jobs). Self-reported pesticide use falling outside Environmental Protection Agency (EPA) approval dates was not included. For cigarette smoking, we classified individuals who smoked more than 100 cigarettes before their reference date as exposed (Grant et al. 2004). Family history of PD was positive if the subject reported PD in any first-degree relative. We dichotomized educational level as ≤12 years and >12 years.

Statistical Analyses: We compared participant characteristics using Fisher’s exact test or Pearson’s chi-square statistic for categorical data and the Wilcoxon rank-sum test for continuous data. For pesticides reported by 10 or more subjects, we evaluated associations between pesticide use and PD using unconditional logistic regression to derive odds ratios (ORs) and 95% confidence intervals (CIs) (Supplemental Table 2). To control potential confounding, we included reference age (tertiles 40-57, 58-65, 66-87 years), gender, state and cigarette smoking (ever/never) in all models. We also examined whether adjusting for overall pesticide use or educational level changed point estimates (±15%) for individual pesticides. To adjust for overall pesticide use, we categorized individuals who used pesticides on fewer than 25 lifetime days as unexposed and others as exposed, using data reported at enrollment in the AHS (data from AHS data release version #P1REL0506 and AHSREL0612).

We performed analyses for pesticide exposure groups classified by mechanism as complex I inhibitors or oxidative stressors based on literature review (Degli Esposti 1998; Krieger 2001; Uversky et al. 2001) and information in public databases (Agency
for Toxic Substances and Disease Registry (ATSDR) 2002; Extension Toxicology
Network (EXTOXNET) 2002; PubChem 2002). Because men were the primary users of
pesticides, we repeated analyses of ever use and duration of use restricted to men. For
each pesticide reported by more than 30 men (Supplemental Table 3), we assessed the
effect of exposure duration by separately comparing less use (at or below the median
number of cumulative days of use) or more use (use above the median) to never use of
that pesticide.

We repeated primary analyses in subgroups defined by race/ethnicity (non-Hispanic
whites, others), state, family history of PD, cigarette use and respondent status (self-
reported vs. proxy-reported pesticide data) and, in cases, PD duration. We performed
analyses for rotenone and paraquat use truncated 5, 10 and 15 years before the index
date to evaluate whether the association of PD with pesticide use was influenced by
behavioral changes caused by undiagnosed disease. We also assessed the
combination of paraquat plus any dithiocarbamate (ferbam, mancozeb, maneb, metam
sodium, vegedex, zineb, ziram) because a previous study reported an association of PD
with the combination of paraquat and the dithiocarbamate maneb (Costello et al. 2009;
Thiruchelvam et al. 2000). We also repeated the primary analysis after including cases
of atypical parkinsonism in our case group. In cases, we compared clinical features in
persons who did or did not use paraquat or oxidative stressors as a group, or rotenone
or complex I inhibitors as a group.

We used SAS version 9.1.3 (SAS Institute, Cary, NC) and SPSS version 12.0 (SPSS
Inc., Chicago, IL) for statistical analyses. We used $\leq 0.05$ as a criterion for statistical
significance.
Results

We identified 170 suspect cases and 644 potential controls and screened 156 (92%) and 542 (84%) of these, respectively (Figure 1). We conducted study evaluations in 137 (88%) of eligible suspect cases (including four initially indentified as potential controls who self-reported PD at screening) and 383 (71%) of eligible potential controls. Final diagnoses in suspect cases were PD (115), essential tremor/other tremor disorder (12), no neurologic diagnosis (5), dystonia (2), multiple system atrophy (2), and atypical parkinsonism not fulfilling any diagnostic criterion (1) (the latter three cases subsequently termed “atypical parkinsonism”).

The analyses reported here include 110 PD cases and 358 controls who provided complete information on pesticide use and application practices. Cases and controls were similar for most characteristics assessed (Table 2), although cases were more likely to have impaired smell recognition or to have a family history of PD, and less likely to smoke.

To validate our approach to pesticide exposure assessment, we compared information on use of 4 pesticides collected at enrollment in the AHS with information collected for FAME. Despite an average lapse of 9 years, agreement was good (DDT 79%, 2,4-D 84%, paraquat 85%, rotenone 93%).

Ninety-eight percent of men and 44% of women had ever used pesticides. Information on 18 pesticides used by more than 10 subjects is presented in Supplemental Table 2. Results from analyses in men were similar to those in men and women combined
(Supplemental Table 2). Information on pesticides linked to Complex I inhibition or oxidative stress, regardless of the number of users, is presented in Table 3. Most of the pesticides in the oxidative stressor and mitochondrial inhibitor groups were infrequently used, limiting individual analyses, but, in general, use of these chemicals was more common in cases. Use of paraquat (OR 2.5, 95% C.I. 1.4, 4.7) or any of the group of oxidative stressors (OR 2.0, 95% C.I. 1.2, 3.6) was associated with PD (Table 3). Similarly, use of rotenone (OR 2.5, 95% C.I. 1.3, 4.7) or any of the group of Complex I inhibitors (OR 1.7, 95% C.I. 1.0, 2.8) was associated with PD (Table 3).

Associations between ever use of paraquat or rotenone and PD were similar when exposures were truncated at 5, 10 or 15 years prior to the diagnosis or reference date (paraquat: 5 years prior OR 2.7 (95% CI 1.4, 4.9), 10 years OR 2.9 (95% CI 1.6, 5.5), 15 years OR 3.1 (95% CI 1.6, 5.8); rotenone: 5 years prior OR 2.3 (95% CI 1.2, 4.4), 10 years OR 2.4 (95% CI 1.3, 4.6), 15 years OR 2.4 (95% CI 1.3, 4.6). Exposures to rotenone and paraquat were not correlated (r = 0.004), and ORs from a model that included both pesticides (paraquat OR 2.6, 95% CI 1.4, 4.9; rotenone OR 2.9, 95% CI 1.5, 5.5) were comparable to those from models without mutual adjustment (Table 3). For men who used paraquat plus any dithiocarbamate (7 cases, 16 controls), the OR compared to use of neither was 2.2 (95% CI 0.79, 5.9). Compared to never users, associations with PD were generally stronger among those who had used pesticides for more than the median number of lifetime days than among those who had used pesticides for fewer than the median number of days (Supplemental Table 3).

Results from analyses stratified by race/ethnicity, cigarette use, state or duration of disease (in cases) were not appreciably different between subgroups (data not shown).
In an analysis restricted to 18 cases and 22 controls (28 men and 12 women) with a first-degree relative with PD, PD was not associated with ever exposure to rotenone (OR 0.98) or paraquat (OR 1.1). Adjustment for education or overall pesticide use did not appreciably alter effect estimates nor did exclusion of 28 cases and 6 controls with proxy interviews or inclusion of 3 atypical parkinsonism cases.

We compared clinical features of cases who did or did not use paraquat or any oxidative stressor, or rotenone or any Complex I inhibitor (Table 4). PD was diagnosed at a younger age among those who used oxidative stressors (mean age 59 vs. 64 years, p = 0.02). Although postural reflex impairment appeared to be less frequent in those using either paraquat or rotenone, these differences were not statistically significant. Clinical features did not otherwise differ between groups. We were unable to determine whether exposure to both paraquat and rotenone was associated with unique clinical features because only 5 cases reported use of both pesticides (data not shown).

Discussion
The pathogenesis of PD is thought to involve several critical abnormalities, each of which can be the result of genetic or environmental factors. Chief among these are dysfunction of the mitochondrial respiratory chain, particularly Complex I, and the production of reactive oxygen species (Henchcliffe and Beal 2008). We have performed the first analysis of pesticides classified by presumed mechanism, rather than by functional categories (e.g., herbicides) or chemical class (e.g., organochlorines). We found significant associations of PD with use of groups of pesticides classified as Complex I inhibitors or as oxidative stressors, providing support in humans for findings from decades of experimental work. In particular, PD was strongly associated with
rotenone and paraquat, two individual pesticides used extensively to model PD in the laboratory.

This study provides strong evidence of an association between rotenone use and PD in humans. PD developed 2.5 times as often in those who reported use of rotenone compared with non-users, and an association of similar magnitude was observed even when exposure was truncated up to 15 years before PD diagnosis. In our prior analysis of self-reported PD in the AHS, information on rotenone was available for a small subgroup, and nonsignificant association with PD (OR 1.7, 95% CI 0.6, 4.7) was observed (Kamel et al. 2007), while in a multicenter, clinic-based case-control study distinct from the AHS, only 2 individuals were exposed and no association was observed (Tanner et al. 2009). In the only other report of rotenone-like compounds and PD, use of “organic pesticides such as rotenone” in the previous year was determined for PD clinic attendees, who reported current use more often than did cases with other neurologic diseases (Dhillon et al. 2008). This information cannot be used to assess etiology because the study evaluated associations with rotenone use that occurred after PD had been diagnosed. In contrast, in the present population-based study, we evaluated rotenone use prior to PD diagnosis in cases, and during a comparable time period in neurologically healthy controls.

Rotenone is a plausible cause of PD because of its mechanism of action. Like 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a toxicant known to cause parkinsonism in humans, rotenone directly inhibits mitochondrial Complex I (Langston et al. 1983; Sherer et al. 2007). In experimental models, both MPTP and rotenone cause selective injury of dopaminergic neurons in the substantia nigra, a key pathological
feature of PD (Greenamyre et al. 1999; Langston et al. 1984). Because rotenone is believed to have a relatively short environmental half-life and limited bioavailability, a relationship to human disease has been questioned (Hatcher et al. 2008; Li et al. 2005).

However, recent work in rodent models indicated that a temporally limited exposure to rotenone later caused progressive functional and pathologic changes in the enteric nervous system of rodents, mimicking changes found in human PD, and, as in PD, these enteric nervous system changes preceded CNS pathology (Abbott et al. 2001; Braak et al. 2006; Drolet et al. 2009; Greene et al. 2009; Pan-Montojo et al. 2010).

Chronic rotenone exposure in the laboratory has been reported to have additional effects associated with PD pathogenesis, including ones similar to changes observed in monogenic forms of PD (Henchcliffe and Beal 2008). Rotenone toxicity, therefore, provides a conceptual bridge, suggesting shared mechanisms for both sporadic and inherited forms of PD.

Although we report here findings for agricultural use of rotenone, the ubiquitous use of rotenone in both work and home settings that occurred until recently suggests that many people may have been exposed. Humans have used rotenone-containing plants as pesticides for centuries (Cabras et al. 2002). Because rotenone is plant-derived, it has been considered an "organic" pesticide, and was commonly used as a household insecticide, in home gardening and agriculture, and to kill fish. For example, the California Department of Pesticide Regulation reported that almost 15,000 pounds of rotenone were used in 2007, not including home use. Rotenone was withdrawn from use in the European Union in 2007 (Schapira 2010), after which time most uses were voluntarily cancelled in the USA (EPA 2007). Other agents associated with mitochondrial Complex I inhibition remain in common use. For example, permethrin is
used in non-agricultural settings as an insect repellant, including use of permethrin-impregnated fabric for military uniforms and recreational clothing (Armed Forces Pest Management Board 2010).

The present study also extends prior research on paraquat. Experimentally, paraquat produces subcellular changes associated with PD, including increased production of reactive oxygen species, alpha-synuclein aggregation and selective nigral injury (Dinis-Oliveira et al. 2006; Kuter et al. 2010; McCormack et al. 2002). Previously we found an association between paraquat use and PD in prevalent but not incident self-reported cases in the AHS (Kamel et al. 2007) and a nonsignificant association between PD and occupational paraquat use in a multicenter case-control study (Tanner et al. 2009). Cumulative use was not assessed in either study. Only a few other studies have assessed associations between PD and paraquat use (Table 1). A study of 120 cases and 240 controls conducted in Taiwan (Liou et al. 1997) reported an OR of 3.22 (95% CI 2.41, 4.31) for PD in paraquat users compared with non-users. Cumulative exposure was associated with greater risk, but paraquat use in the Taiwanese study was highly correlated with use of other herbicides. Although the inconsistency of findings in human populations has been used as a basis for suggesting that paraquat is not associated with PD (Li et al. 2005; Miller 2007), an alternative explanation is that few studies have had adequate size and sufficiently detailed exposure information to allow the association to be observed. The present findings, considered together with earlier results, suggest that paraquat use plays a role in human PD. Because paraquat remains one of the most widely used herbicides worldwide (Frabotta 2009), this finding potentially has great public health significance.
Parkinsonism in humans due to high-dose exposure to toxicants such as carbon monoxide or manganese has characteristic clinical features including less prominent tremor, more prominent postural instability, symmetric distribution of signs and poor response to dopaminergic therapy (Tanner 1992). We did not observe such features in our cases. Cases who did or did not use rotenone, paraquat, or groups of pesticides with similar mechanisms were generally similar, suggesting that PD associated with these agents is clinically typical, and indirectly supporting a role for pesticide exposure in the etiology of typical PD. We did note an earlier age at diagnosis in users of oxidative stressors, and a suggestion of this in paraquat users specifically. Early age at onset is also a characteristic of genetic parkinsonism in which oxidative stress is a presumed pathophysiologic mechanism (*alpha*-synuclein, *PINK-1*, *DJ-1* and *PARKIN* mutations) (Henchcliffe and Beal 2008; Klein et al. 2009).

In FAME, pesticide exposure was not associated with PD in individuals with a family history, although numbers were small. Interestingly, Hancock and colleagues similarly found pesticide exposure to be associated with PD risk only in those without an affected first-degree relative (Hancock et al. 2008).

Our study has some limitations. Because most participants were exposed to many pesticides, we cannot confidently exclude effects of agents other than those studied, or rule out the possibility that our results are due to combined exposures. However, the associations that we observed remained after adjustment for overall pesticide use, and estimated effects of rotenone and paraquat were comparable after mutual adjustment. Future investigations of combinations of pesticides and of other mechanistic groups will be important. Second, we could not use laboratory measures of pesticides or their
metabolites to estimate exposure. Such measures are not available for many of the pesticides we studied, and, when available, they are poor predictors of past or long-term use. Thus, while we recognize that retrospective exposure assessment has limitations, it is often the best approach for studying lifelong exposure in an adult population in connection with a rare disease. Third, we included prevalent cases already diagnosed but still living at enrollment in the AHS, and therefore, survivor bias is possible; however, our results were similar when only those with shorter disease duration were analyzed. Additionally, we were able to investigate only persons willing to participate. Thus, PD cases or controls in this study may not have been fully representative of the entire population. However, participation was good, partially allaying this concern. Finally, we selected pesticides presumed to act through specific toxic mechanisms, but for most pesticides there is very little information regarding toxic effects in humans, as most studies are directed toward effects on plant or animal pests. It is likely that we have misclassified some pesticides with regard to mechanism. However, the likely effect of any misclassification would be to attenuate an association with pesticides grouped according to a common mechanism.

Strengths include the size of the study; the focus on an agricultural cohort with many exposed individuals and wide variability in exposure; the quality of diagnosis, which was based on in-person assessment and agreement of movement disorders experts; and the completeness and reliability of the pesticide exposure information. An additional strength is the nested case-control design with an internal control group who had similar exposure opportunities as the cases and similar demographic and lifestyle characteristics, reducing the likelihood of bias or confounding. Use of pesticides in general was of course ubiquitous in applicators, and relatively common among their
spouses, and all participants may have had additional passive pesticide exposure. However, these features would all be likely to lower the chance of identifying any effect.

The current study helps connect the dots between basic research and human populations. Rotenone and paraquat have been linked experimentally to pathophysiological mechanisms implicated in human PD. Groups of pesticides linked to the mechanisms of mitochondrial dysfunction or oxidative stress were also associated with PD in our study, thus extending experimental work to provide strong evidence that these mechanisms play a role in PD in humans. It is important to note that the potential for exposure to many of these pesticides, including rotenone and paraquat, extends well beyond the occupational setting. Many persons with non-occupational pesticide exposures may be unaware of the presence of pesticides in their environments (CDC 2009). The potential for exposure to other toxicants with similar mechanisms is even greater. To continue the interplay between human and experimental studies, future mechanistic studies of these pesticides should model exposure conditions similar to those occurring in humans, including chronic low-dose exposure, exposure to multiple agents, and assessment of gene-exposure interactions. Such work could provide new insights into the pathogenesis and, ultimately, the prevention of PD.
References


EPA (Environmental Protection Agency. 2007. Environmental Protection Agency (March 2007) EPA 738-R-07-005:


EXTOXNET (Extension Toxicology Network). 2002. Retrieved in 2002 from: Extension Toxicology Network Website:


Potentiated and preferential effects of combined paraquat and maneb on
nigrostriatal dopamine systems: environmental risk factors for Parkinson's

Neurol 5(1):75-86.

Uversky VN, Li J, Fink AL. 2001. Pesticides directly accelerate the rate of alpha-
500(3):105-108.
<table>
<thead>
<tr>
<th>Citation, date</th>
<th>Design</th>
<th>Method of assessing pesticide use</th>
<th>Number enrolled Cases, Controls</th>
<th>Finding</th>
<th>Odds Ratios (95% CI) or p-value</th>
<th>Exposed N</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Paraquat</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sanchez-Ramos et al. 1987</td>
<td>Case report</td>
<td>Medical history</td>
<td>1 case</td>
<td>Symptoms “comparable to PD” in a 32-year-old farmer following 15 years paraquat use</td>
<td>NA</td>
<td>1 case</td>
</tr>
<tr>
<td>Hertzman et al. 1990</td>
<td>Case-control</td>
<td>Specific question re: paraquat use</td>
<td>57 cases</td>
<td>Association with PD</td>
<td>p = 0.01*</td>
<td>4 cases</td>
</tr>
<tr>
<td>Semchuk et al. 1992</td>
<td>Case-control</td>
<td>General questions re: pesticide use</td>
<td>130 cases</td>
<td>One case with early onset PD (&lt;age 40 years) reported using paraquat (ages 26 – 31)</td>
<td>NA</td>
<td>1 case</td>
</tr>
<tr>
<td>Hertzman et al. 1994</td>
<td>Case-control</td>
<td>Specific question re: paraquat use</td>
<td>127 cases</td>
<td>No association with PD</td>
<td>1.11 (0.32, 3.87)</td>
<td>6 cases</td>
</tr>
<tr>
<td>Liou et al. 1997</td>
<td>Case-control</td>
<td>Open-ended question re: pesticide use</td>
<td>120 cases</td>
<td>No association with PD</td>
<td>1.25 (0.34, 4.63)</td>
<td>6 cases</td>
</tr>
<tr>
<td>Firestone et al. 2005</td>
<td>Case-control</td>
<td>Checklist**</td>
<td>250 cases</td>
<td>Association with PD</td>
<td>3.22 (2.41, 4.31)</td>
<td>31 cases</td>
</tr>
<tr>
<td>Kamel et al. 2007</td>
<td>Case-control</td>
<td>Specific question re: paraquat use</td>
<td>83 prevalent cases</td>
<td>Association with PD in prevalent cases</td>
<td>1.8 (1.0, 3.4)</td>
<td>14 prevalent</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>79,557 controls</td>
<td></td>
<td></td>
<td>11,266 controls</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>78 incident cases</td>
<td>No association with PD in incident cases</td>
<td>1.0 (0.5, 1.9)</td>
<td>11 incident</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>55,931 controls</td>
<td></td>
<td></td>
<td>7,382 controls</td>
</tr>
<tr>
<td>Tanner et al. 2009</td>
<td>Case-control</td>
<td>Specific question re: occupational paraquat use</td>
<td>519 cases</td>
<td>Association with PD</td>
<td>2.80 (0.81, 9.72)</td>
<td>9 cases</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>511 controls</td>
<td></td>
<td></td>
<td>4 controls</td>
</tr>
<tr>
<td>Firestone et al, 2010</td>
<td>Case-control</td>
<td>Checklist*</td>
<td>404 incident cases</td>
<td>Added subjects to 2005 interim population</td>
<td>0.9 (0.14, 5.43)</td>
<td>2 cases</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>526 controls</td>
<td>No association with PD in re-analysis</td>
<td></td>
<td>3 controls</td>
</tr>
<tr>
<td><strong>Rotenone</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kamel et al. 2007</td>
<td>Case-control</td>
<td>Specific question re: rotenone use in a supplementary questionnaire</td>
<td>83 prevalent cases</td>
<td>Association of PD with ever use</td>
<td>1.7 (0.6, 4.7)</td>
<td>4 prevalent</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>79,557 controls</td>
<td></td>
<td></td>
<td>671 controls</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>78 incident cases</td>
<td>Could not determine</td>
<td></td>
<td>1 incident</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>55,931 controls</td>
<td></td>
<td></td>
<td>565 controls</td>
</tr>
<tr>
<td>Study</td>
<td>Design</td>
<td>Question</td>
<td>Cases/Frequency</td>
<td>Association with PD</td>
<td>Effect Size (95% CI)</td>
<td>Cases/Frequency</td>
</tr>
<tr>
<td>------------------</td>
<td>--------------</td>
<td>---------------------------</td>
<td>-----------------</td>
<td>---------------------</td>
<td>----------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Tanner et al. 2009</td>
<td>Case-control</td>
<td>Specific question re: occupational rotenone use</td>
<td>519 cases/511 controls</td>
<td>No association with PD</td>
<td>0.82 (0.05, 13.34)</td>
<td>1 case/1 control</td>
</tr>
<tr>
<td>Dhillon et al. 2008</td>
<td>Case-control</td>
<td>General question re: “organic pesticides”</td>
<td>100 cases/84 controls</td>
<td>Greater use of “organic pesticides such as rotenone” in PD patients</td>
<td>10.0 (2.9, 34.3)</td>
<td>27 cases/3 controls</td>
</tr>
</tbody>
</table>

* 4 PD patients and no controls reported paraquat contact; OR could not be calculated; ** Occupational pesticide exposures were identified from a checklist of common chemical agents and home-based pesticide exposures from a checklist of commercial brand name products; * Subjects reported exposures to various industrial toxicants identified from a checklist.
Table 2: Characteristics of Subjects

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Cases</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>110</td>
<td>358</td>
</tr>
<tr>
<td>Age at FAME enrollment, mean +/- SD, years</td>
<td>70 ± 8</td>
<td>69 ± 8</td>
</tr>
<tr>
<td>Men, N (%)</td>
<td>80 (73)</td>
<td>265 (74)</td>
</tr>
<tr>
<td>Residence in Iowa (vs. North Carolina), N (%)</td>
<td>79 (72)</td>
<td>262 (73)</td>
</tr>
<tr>
<td>NonHispanic white (vs. other), N (%)</td>
<td>107 (97)</td>
<td>350 (98)</td>
</tr>
<tr>
<td>Pesticide applicator (vs. spouse), N (%)</td>
<td>80 (73)</td>
<td>267 (75)</td>
</tr>
<tr>
<td>Education &gt; high school, N (%)</td>
<td>49 (45)</td>
<td>178 (50)</td>
</tr>
<tr>
<td>PD in 1st-degree relative, N (%)</td>
<td>18 (16)</td>
<td>22 (6)*</td>
</tr>
<tr>
<td>Smoked at least 100 cigarettes, N (%)</td>
<td>31 (28)</td>
<td>141 (39)**</td>
</tr>
<tr>
<td>BSIT, mean score +/- SD</td>
<td>5.5 ± 2.8</td>
<td>8.8 ± 2.3#</td>
</tr>
<tr>
<td>CASI, mean score +/- SD</td>
<td>89.2 ± 8.5</td>
<td>93.1 ±5.0&quot;</td>
</tr>
</tbody>
</table>

**Clinical Features among Cases**

- **Age at PD diagnosis, mean years +/- SD**: 61 ± 9
- **PD duration at FAME enrollment, median years +/- SD**: 7 ± 6
- **Resting tremor, N affected / N with data (%)**: 100/108 (93)
- **Bradykinesia, N affected / N with data (%)**: 105/110 (95)
- **Rigidity, N affected / N with data (%)**: 106/107 (99)
- **Postural reflex impairment, N affected / N with data (%)**: 61/92 (66)
- **Asymmetric onset, N affected / N with data (%)**: 102/104 (98)
- **Response to dopaminergic therapy (if prescribed), N affected / N with data (%)**: 95/98 (97)

Abbreviations: BSIT- Brief Smell Identification Test; CASI- Cognitive Abilities Screening Instrument; N- Number; PD- Parkinson’s disease; SD- Standard deviation

*Percentages for clinical features are based on numbers of cases with features divided by the total number of cases with available data; cases with missing data for a feature are excluded.

*p < 0.005 (Fisher’s exact test); **p < 0.05 (Fisher’s exact test); "p < 0.001 (Wilcoxon rank sum test)
Table 3: Association of PD with Ever Use of Pesticides Before Diagnosis or Reference Date by Mechanism

<table>
<thead>
<tr>
<th>Pesticide</th>
<th>Cases (N=110) N (%)</th>
<th>Controls (N=358) N (%)</th>
<th>OR</th>
<th>95% CI</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oxidative Stressors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paraquat</td>
<td>23 (24)</td>
<td>49 (14)</td>
<td>2.5</td>
<td>1.4-4.7</td>
<td>0.004</td>
</tr>
<tr>
<td>Permethrin</td>
<td>16 (16)</td>
<td>41 (12)</td>
<td>1.5</td>
<td>0.77-2.9</td>
<td>0.244</td>
</tr>
<tr>
<td>Carbon disulfide</td>
<td>2 (2)</td>
<td>3 (1)</td>
<td>2.6</td>
<td>0.41-16</td>
<td>0.313</td>
</tr>
<tr>
<td>Chloranil</td>
<td>1 (1)</td>
<td>3 (1)</td>
<td>1.6</td>
<td>0.16-16</td>
<td>0.706</td>
</tr>
<tr>
<td>Cyhalothrin</td>
<td>1 (1)</td>
<td>1 (0)</td>
<td>3.8</td>
<td>0.22-64</td>
<td>0.359</td>
</tr>
<tr>
<td>Dichlone</td>
<td>3 (3)</td>
<td>8 (2)</td>
<td>1.6</td>
<td>0.40-6.2</td>
<td>0.517</td>
</tr>
<tr>
<td>Mercury compounds</td>
<td>2 (2)</td>
<td>5 (1)</td>
<td>1.4</td>
<td>0.26-7.5</td>
<td>0.692</td>
</tr>
<tr>
<td>Pybuthrin</td>
<td>0 (0)</td>
<td>6 (2)</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any oxidative stressor</td>
<td>35 (40)</td>
<td>93 (28)</td>
<td>2.0</td>
<td>1.2-3.6</td>
<td>0.012</td>
</tr>
<tr>
<td><strong>Mitochondrial Complex I Inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benomyl</td>
<td>7 (7)</td>
<td>15 (4)</td>
<td>1.9</td>
<td>0.70-5.0</td>
<td>0.207</td>
</tr>
<tr>
<td>Carbendazim</td>
<td>1 (1)</td>
<td>2 (1)</td>
<td>2.2</td>
<td>0.19-25</td>
<td>0.529</td>
</tr>
<tr>
<td>Cyhalothrin</td>
<td>1 (1)</td>
<td>1 (0)</td>
<td>3.8</td>
<td>0.22-64</td>
<td>0.359</td>
</tr>
<tr>
<td>Permethrin</td>
<td>16 (16)</td>
<td>41 (12)</td>
<td>1.5</td>
<td>0.77-2.9</td>
<td>0.244</td>
</tr>
<tr>
<td>Pyridaben</td>
<td>0 (0)</td>
<td>1 (0)</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotenone</td>
<td>19 (19)</td>
<td>32 (9)</td>
<td>2.5</td>
<td>1.3-4.7</td>
<td>0.005</td>
</tr>
<tr>
<td>Thiabendazole</td>
<td>3 (3)</td>
<td>12 (3)</td>
<td>0.8</td>
<td>0.23-3.1</td>
<td>0.778</td>
</tr>
<tr>
<td>Any Complex I inhibitor</td>
<td>36 (38)</td>
<td>92 (27)</td>
<td>1.7</td>
<td>1.0-2.8</td>
<td>0.041</td>
</tr>
</tbody>
</table>

Abbreviations: CI - Confidence interval; N - Number; NA - Not available; OR - Odds ratio; PD - Parkinson’s disease

Legend for Table 2: Analyses used logistic regression adjusted for reference age tertile, gender, state, and cigarette smoking.
Table 4: Clinical Features of PD Cases, by Use of Paraquat or Rotenone or Mechanistic Group

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Paraquat</th>
<th>Any Oxidative Stressor</th>
<th>Rotenone</th>
<th>Any Complex I Inhibitor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at PD diagnosis, mean +/- SD, years</td>
<td>59 ± 8</td>
<td>62 ± 9</td>
<td>59 ± 8</td>
<td>64 ± 9*</td>
</tr>
<tr>
<td>PD duration, mean +/- SD, years</td>
<td>8.6 ± 6</td>
<td>8.4 ± 6</td>
<td>8.2 ± 6</td>
<td>7.6 ± 5</td>
</tr>
</tbody>
</table>

Clinical features (number with feature by number with data available, %)

| Resting tremor                           | 21/22 (95)66/73 (90)      | 31/34 (91)49/53 (92)   | 17/18 (94)75/81 (93)     | 32/35 (91)54/58 (93)    |
| Bradykinesia                             | 22/23 (96)70/74 (95)      | 33/35 (94)50/53 (94)   | 17/19 (89)79/82 (96)     | 34/36 (94)56/59 (95)    |
| Rigidity                                 | 23/23 (100)72/73 (99)     | 33/34 (97)50/53 (94)   | 18/19 (95)80/80 (100)    | 34/35 (97)58/58 (100)   |
| Postural reflex                          | 10/21 (48)43/62 (69)      | 18/31 (58)29/43 (67)   | 7/15 (47)48/69 (70)      | 16/28 (57)37/52 (71)    |
| Impairment                               | 23/23 (100)69/71 (97)     | 35/35 (100)49/51 (96)  | 18/18 (100)77/79 (97)    | 35/35 (100)54/56 (96)   |
| Asymmetric onset                         | 21/21 (100)63/65 (97)     | 30/30 (100)46/48 (96)  | 14/15 (93)73/74 (99)     | 30/31 (97)53/54 (98)    |
| Response to dopaminergic therapy (if prescribed) | 21/21 (100)63/65 (97)     | 30/30 (100)46/48 (96)  | 14/15 (93)73/74 (99)     | 30/31 (97)53/54 (98)    |

Abbreviations: PD- Parkinson’s disease; SD- Standard deviation

* Difference between exposed vs. not exposed p = 0.02
Figure Legend

Figure 1. We identified 170 suspect cases and 644 potential controls and screened 156 (92%) and 542 (84%) of these, respectively. We conducted study evaluations in 137 (88%) of eligible suspect cases (including four initially identified as potential controls who self-reported PD at screening) and 383 (71%) of eligible potential controls. Suspect cases were evaluated in home visits or from medical records, matched controls in home visits. Final diagnoses in suspect cases were PD (115), essential tremor/other tremor disorder (12), no neurologic diagnosis (5), dystonia (2), multiple system atrophy (2), and atypical parkinsonism not fulfilling any diagnostic criterion (1) (the latter three cases subsequently termed “atypical parkinsonism”).